REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$13.64 USD
+0.14 (1.04%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $13.50 -0.14 (-1.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for REGENXBIO Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 90 | 113 | 470 | 155 | 35 |
Cost Of Goods | 37 | 55 | 52 | 36 | 8 |
Gross Profit | 53 | 58 | 419 | 119 | 27 |
Selling & Adminstrative & Depr. & Amort Expenses | 321 | 321 | 259 | 238 | 176 |
Income After Depreciation & Amortization | -268 | -263 | 160 | -119 | -149 |
Non-Operating Income | 11 | 6 | 8 | 14 | 52 |
Interest Expense | 7 | 23 | 26 | 1 | 0 |
Pretax Income | -264 | -280 | 141 | -106 | -97 |
Income Taxes | 0 | 0 | 13 | 5 | -3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -263 | -280 | 128 | -111 | -95 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -263 | -280 | 128 | -111 | -95 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -250 | -245 | 175 | -110 | -143 |
Depreciation & Amortization (Cash Flow) | 18 | 18 | 15 | 9 | 6 |
Income After Depreciation & Amortization | -268 | -263 | 160 | -119 | -149 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.73 | 43.15 | 43.91 | 37.28 | 36.69 |
Diluted EPS Before Non-Recurring Items | -6.02 | -6.33 | 2.91 | -2.98 | -3.26 |
Diluted Net EPS (GAAP) | -6.02 | -6.50 | 2.91 | -2.98 | -2.58 |
Fiscal Year end for REGENXBIO Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 15.62 | 22.21 | 28.91 | 19.98 |
Cost Of Goods | NA | 4.28 | 11.24 | 12.39 | 9.48 |
Gross Profit | NA | 11.34 | 10.98 | 16.53 | 10.50 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 75.20 | 74.88 | 81.48 | 83.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -63.86 | -63.90 | -64.95 | -73.11 |
Non-Operating Income | NA | 2.51 | 2.23 | 4.72 | 2.17 |
Interest Expense | NA | 1.97 | 1.36 | 1.62 | 1.12 |
Pretax Income | NA | -63.33 | -63.04 | -61.87 | -72.06 |
Income Taxes | NA | 0.00 | -0.15 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -63.33 | -62.89 | -61.87 | -72.06 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -63.33 | -62.89 | -61.87 | -72.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 45.73 | 44.00 | 43.95 | 43.53 |
Diluted EPS Before Non-Recurring Items | NA | -1.38 | -1.43 | -1.41 | -1.66 |
Diluted Net EPS (GAAP) | NA | -1.38 | -1.42 | -1.41 | -1.66 |